Article
Author: Mbau, Lilian ; Adamska, Agnieszka ; Ray, Kausik K ; De Backer, Guy ; De Bacquer, Dirk ; Li, Yong ; Triana, Miguel Alberto Urina ; Johansson, Isabelle ; Rydén, Lars ; Makubi, Abel ; Estrada, Jose Luis Navarro ; Jankowski, Piotr ; Al-Azzawy, Safi Moayad ; Yeo, Tee Joo ; Ambari, Ade Meidian ; Hasan-Ali, Hosam ; Vihervaara, Terhi ; Tan, Jack Wei Chieh ; Sani, Mahmoud Umar ; Erlund, Iris ; Mbakwem, Amam Chinyere ; Ogola, Elijah Nyainda ; Ge, Junbo ; McEvoy, John William ; Lip, Gregory Y H ; Ganly, Sandra ; Almahmeed, Wael ; Liprandi, Maria Ines Sosa ; Quintero-Baiz, Adalberto ; Kotseva, Kornelia ; Wood, David ; Abreu, Ana ; Mellbin, Linda ; Ogah, Okechukwu Samuel ; Huo, Yong ; Jennings, Catriona ; Jimenez, Rodney M ; Zuhdi, Syadi Mahmood
OBJECTIVE:Dysglycaemia, defined as type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), increases the cardiovascular risk and prognosis. INTERASPIRE performed in 14 countries across 6 WHO regions evaluated guideline adherence and management of patients with coronary artery disease (CAD) and dysglycaemia.
METHODS:A total of 4,548 CAD patients (18-80 years) were interviewed 6 months-2 years after hospital admission. All without diabetes were eligible for an oral glucose test (OGTT).
RESULTS:Overall, 1990 (44%) had known T2DM. The OGTT revealed that 808 (40%) had previously unknown dysglycaemia (T2DM 12% and IGT 28%). Two thirds of all dysglycaemic patients were obese. A similar proportion reported low physical activity and only one third received dietary advice. Only half of dysglycemic patients were prescribed all guideline recommended cardioprotective drugs. A majority did not reach recommended blood pressure, lipids or HbA1c targets. Only 16% had attended a diabetes education program.
CONCLUSIONS:The INTERASPIRE study shows that screening for glucose perturbations in coronary patients is inadequate, achievement of lifestyle recommendations suboptimal and pharmacological management insufficient resulting in a poor risk factor control. Patients with coronary disease, especially those with glucose perturbations require professional support to achieve healthier lifestyles, and prescription of all cardioprotective medications to achieve guideline targets.